Newlan's Truism: An "acceptable" level of unemployment means that the government economist to whom it is acceptable still has a job.
I get asked quite a bit this time of year of what my favorite growth play among large cap concerns in the biotech sector is for the year ahead. One name continues to stand out. It is a name not surprisingly that is showing up in the top large cap picks list within biotech for 2017 at such places as Merrill Lynch and RBC Capital.
Celgene (NASDAQ:CELG) should be known to just about every biotech investor. I can think of no other large cap industry player that has a clearer earnings growth trajectory over the next 3-5 years. Celgene is not going to be "home run" investment, but I expect it to continue to deliver "singles" every year with an occasional "double" in some years.
